|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHTKD1 |
Gene summary for DHTKD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHTKD1 | Gene ID | 55526 |
| Gene name | dehydrogenase E1 and transketolase domain containing 1 | |
| Gene Alias | AAKAD | |
| Cytomap | 10p14 | |
| Gene Type | protein-coding | GO ID | GO:0002244 | UniProtAcc | Q96HY7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55526 | DHTKD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.56e-05 | 3.64e-01 | -0.1954 |
| 55526 | DHTKD1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.17e-04 | 3.15e-01 | -0.1464 |
| 55526 | DHTKD1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.93e-04 | 4.14e-01 | -0.059 |
| 55526 | DHTKD1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.48e-07 | 4.75e-01 | 0.0674 |
| 55526 | DHTKD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.42e-02 | 3.88e-01 | 0.3859 |
| 55526 | DHTKD1 | F007 | Human | Colorectum | FAP | 3.28e-02 | -2.20e-01 | 0.1176 |
| 55526 | DHTKD1 | A015-C-203 | Human | Colorectum | FAP | 1.09e-02 | -2.30e-02 | -0.1294 |
| 55526 | DHTKD1 | A002-C-201 | Human | Colorectum | FAP | 3.65e-02 | -1.19e-01 | 0.0324 |
| 55526 | DHTKD1 | A002-C-205 | Human | Colorectum | FAP | 1.50e-03 | -1.00e-01 | -0.1236 |
| 55526 | DHTKD1 | A015-C-104 | Human | Colorectum | FAP | 2.75e-04 | -4.12e-02 | -0.1899 |
| 55526 | DHTKD1 | A002-C-016 | Human | Colorectum | FAP | 2.86e-03 | -1.04e-01 | 0.0521 |
| 55526 | DHTKD1 | A002-C-116 | Human | Colorectum | FAP | 2.17e-05 | -9.99e-02 | -0.0452 |
| 55526 | DHTKD1 | A018-E-020 | Human | Colorectum | FAP | 2.39e-02 | -6.71e-02 | -0.2034 |
| 55526 | DHTKD1 | F034 | Human | Colorectum | FAP | 4.13e-02 | -9.58e-02 | -0.0665 |
| 55526 | DHTKD1 | LZE2T | Human | Esophagus | ESCC | 1.33e-03 | 4.75e-01 | 0.082 |
| 55526 | DHTKD1 | LZE5T | Human | Esophagus | ESCC | 6.66e-03 | 2.21e-01 | 0.0514 |
| 55526 | DHTKD1 | LZE8T | Human | Esophagus | ESCC | 1.45e-02 | 4.55e-02 | 0.067 |
| 55526 | DHTKD1 | LZE24T | Human | Esophagus | ESCC | 3.97e-10 | 2.61e-01 | 0.0596 |
| 55526 | DHTKD1 | P2T-E | Human | Esophagus | ESCC | 5.72e-23 | 4.94e-01 | 0.1177 |
| 55526 | DHTKD1 | P4T-E | Human | Esophagus | ESCC | 1.20e-12 | 2.76e-01 | 0.1323 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00196936 | Liver | NAFLD | ribose phosphate metabolic process | 73/1882 | 396/18723 | 2.23e-07 | 1.53e-05 | 73 |
| GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
| GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
| GO:00060917 | Liver | NAFLD | generation of precursor metabolites and energy | 84/1882 | 490/18723 | 7.03e-07 | 3.95e-05 | 84 |
| GO:00725217 | Liver | NAFLD | purine-containing compound metabolic process | 74/1882 | 416/18723 | 7.73e-07 | 4.27e-05 | 74 |
| GO:00091507 | Liver | NAFLD | purine ribonucleotide metabolic process | 67/1882 | 368/18723 | 1.10e-06 | 5.44e-05 | 67 |
| GO:00091857 | Liver | NAFLD | ribonucleoside diphosphate metabolic process | 28/1882 | 106/18723 | 1.29e-06 | 6.02e-05 | 28 |
| GO:00061637 | Liver | NAFLD | purine nucleotide metabolic process | 70/1882 | 396/18723 | 1.93e-06 | 8.23e-05 | 70 |
| GO:00091357 | Liver | NAFLD | purine nucleoside diphosphate metabolic process | 26/1882 | 103/18723 | 7.51e-06 | 2.55e-04 | 26 |
| GO:00091797 | Liver | NAFLD | purine ribonucleoside diphosphate metabolic process | 26/1882 | 103/18723 | 7.51e-06 | 2.55e-04 | 26 |
| GO:00060907 | Liver | NAFLD | pyruvate metabolic process | 26/1882 | 106/18723 | 1.31e-05 | 3.93e-04 | 26 |
| GO:00460317 | Liver | NAFLD | ADP metabolic process | 23/1882 | 90/18723 | 2.00e-05 | 5.64e-04 | 23 |
| GO:00091327 | Liver | NAFLD | nucleoside diphosphate metabolic process | 28/1882 | 124/18723 | 3.22e-05 | 8.40e-04 | 28 |
| GO:00060967 | Liver | NAFLD | glycolytic process | 21/1882 | 81/18723 | 3.58e-05 | 9.07e-04 | 21 |
| GO:00067577 | Liver | NAFLD | ATP generation from ADP | 21/1882 | 82/18723 | 4.37e-05 | 1.06e-03 | 21 |
| GO:00160526 | Liver | NAFLD | carbohydrate catabolic process | 32/1882 | 154/18723 | 5.29e-05 | 1.21e-03 | 32 |
| GO:00061657 | Liver | NAFLD | nucleoside diphosphate phosphorylation | 22/1882 | 99/18723 | 2.77e-04 | 4.46e-03 | 22 |
| GO:00469397 | Liver | NAFLD | nucleotide phosphorylation | 22/1882 | 101/18723 | 3.73e-04 | 5.60e-03 | 22 |
| GO:00460347 | Liver | NAFLD | ATP metabolic process | 46/1882 | 277/18723 | 4.55e-04 | 6.69e-03 | 46 |
| GO:00159807 | Liver | NAFLD | energy derivation by oxidation of organic compounds | 48/1882 | 318/18723 | 2.78e-03 | 2.54e-02 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00310 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
| hsa003101 | Colorectum | AD | Lysine degradation | 27/2092 | 63/8465 | 1.17e-03 | 7.75e-03 | 4.94e-03 | 27 |
| hsa003102 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
| hsa003103 | Colorectum | MSS | Lysine degradation | 24/1875 | 63/8465 | 2.94e-03 | 1.39e-02 | 8.50e-03 | 24 |
| hsa003104 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
| hsa003105 | Colorectum | FAP | Lysine degradation | 23/1404 | 63/8465 | 1.04e-04 | 9.46e-04 | 5.76e-04 | 23 |
| hsa0031010 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
| hsa0031013 | Esophagus | ESCC | Lysine degradation | 41/4205 | 63/8465 | 9.63e-03 | 2.27e-02 | 1.16e-02 | 41 |
| hsa003108 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
| hsa0031011 | Liver | NAFLD | Lysine degradation | 21/1043 | 63/8465 | 1.09e-05 | 3.58e-04 | 2.89e-04 | 21 |
| hsa003802 | Liver | Cirrhotic | Tryptophan metabolism | 22/2530 | 42/8465 | 1.85e-03 | 8.37e-03 | 5.16e-03 | 22 |
| hsa0031021 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
| hsa0038011 | Liver | Cirrhotic | Tryptophan metabolism | 22/2530 | 42/8465 | 1.85e-03 | 8.37e-03 | 5.16e-03 | 22 |
| hsa0031031 | Liver | Cirrhotic | Lysine degradation | 29/2530 | 63/8465 | 4.81e-03 | 1.74e-02 | 1.07e-02 | 29 |
| hsa0031041 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
| hsa00785 | Liver | HCC | Lipoic acid metabolism | 14/4020 | 19/8465 | 1.89e-02 | 4.40e-02 | 2.45e-02 | 14 |
| hsa0031051 | Liver | HCC | Lysine degradation | 47/4020 | 63/8465 | 1.02e-05 | 7.58e-05 | 4.22e-05 | 47 |
| hsa007851 | Liver | HCC | Lipoic acid metabolism | 14/4020 | 19/8465 | 1.89e-02 | 4.40e-02 | 2.45e-02 | 14 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHTKD1 | SNV | Missense_Mutation | novel | c.1499N>T | p.Pro500Leu | p.P500L | Q96HY7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A7-A6VW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| DHTKD1 | SNV | Missense_Mutation | rs759869851 | c.1249C>T | p.Arg417Cys | p.R417C | Q96HY7 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| DHTKD1 | SNV | Missense_Mutation | c.624N>A | p.Met208Ile | p.M208I | Q96HY7 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
| DHTKD1 | SNV | Missense_Mutation | c.1849N>C | p.Tyr617His | p.Y617H | Q96HY7 | protein_coding | tolerated(0.43) | benign(0.012) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHTKD1 | insertion | Nonsense_Mutation | novel | c.1346_1347insATTGTTTGTGCATTCACTCATCGAACCTTTG | p.Tyr449Ter | p.Y449* | Q96HY7 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| DHTKD1 | insertion | Frame_Shift_Ins | novel | c.2572_2572+1insAT | p.His859IlefsTer43 | p.H859Ifs*43 | Q96HY7 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| DHTKD1 | insertion | Frame_Shift_Ins | novel | c.1998_1999insCCAACTTTTCTCATCT | p.Asp667ProfsTer6 | p.D667Pfs*6 | Q96HY7 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| DHTKD1 | deletion | Frame_Shift_Del | novel | c.360delC | p.Tyr121IlefsTer49 | p.Y121Ifs*49 | Q96HY7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DHTKD1 | deletion | Frame_Shift_Del | novel | c.504delA | p.Lys168AsnfsTer2 | p.K168Nfs*2 | Q96HY7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DHTKD1 | SNV | Missense_Mutation | novel | c.331G>A | p.Glu111Lys | p.E111K | Q96HY7 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |